Idorsia and Pharmalink enter into an exclusive distribution and commercialization agreement for QUVIVIQ™ (daridorexant) in the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and Bahrain Allschwil, CH – Idorsia Ltd has… Read More
BIOTECanada welcomes the launch of the National Research Council of Canada’s Biomedical Countermeasures Initiative, introduced as part of the federal government’s Defence Industrial Strategy. It is an important step in… Read More
Extended agreement will expand manufacturing capacity at Lonza Houston (US) to support growing demand for Genetix’s ZYNTEGLO™ (betibeglogene autotemcel), the only FDA-approved gene therapy for pediatric and adult patients with transfusion… Read More
Advancing Alzheimer’s and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling Activities Targeting Initiation of Phase 1 Clinical Trial in Alzheimer’s Disease in 2027 Vancouver, BC – InMed Pharmaceuticals… Read More
Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall survival versus standard… Read More
